# US 11,304,977 B2 · Tumoricidal and antimicrobial compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,977 B2
- Document ID: US11304977B2
- Status: Granted
- Kind: B2
- Application number: 16/598,418
- Filed: 2019-10-10
- Published: 2020-02-06
- Granted: 2022-04-19
- Earliest claimed: 2013-11-01
- Assignees: ImmunityBio, Inc.
- Applicants: NantKwest, Inc.
- Inventors: Hans G. Klingemann; Barry J. Simon
- Web page: https://patentgrep.com/patent/US11304977B2

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 38/2013: {IL-2}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/44: Fungal antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- Y02A 40/70: in livestock or poultry
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

## Claims

### Claim 1

A composition for treating cancer comprising isolated exosomes or microvesicles from NK-92 cells cultured in a medium supplemented with at least one of a nutrient, a cytokine, or a growth factor.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the medium comprises a cytokine and the cytokine is selected from the group consisting of IL-2, IL-15, interferon gamma and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the medium comprises a nutrient.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the medium comprises a growth factor.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the nutrient is selected from the group consisting of L-asparagine, L-glutamine, L-serine and combinations thereof.